EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.42 (4.24%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $10.33 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EYPT 10.33 +0.42(4.24%)
Will EYPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYPT
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
Other News for EYPT
EyePoint Pharmaceuticals Earns ‘Outperform’ Rating on Promising Duravyu Data and Strategic FDA Alignment
TD Cowen Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Results
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
EyePoint announces developments on DURAVYU